Haemonetics Ebit vs Income Tax Expense Analysis

HAE Stock

USD 90.75 1.03 1.12%

Haemonetics financial indicator trend analysis is much more than just examining Haemonetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Haemonetics is a good investment. Please check the relationship between Haemonetics Ebit and its Income Tax Expense accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Ebit vs Income Tax Expense

Ebit vs Income Tax Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Haemonetics Ebit account and Income Tax Expense. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Haemonetics' Ebit and Income Tax Expense is 0.5. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Haemonetics, assuming nothing else is changed. The correlation between historical values of Haemonetics' Ebit and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Haemonetics are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Ebit i.e., Haemonetics' Ebit and Income Tax Expense go up and down completely randomly.

Correlation Coefficient

0.5

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Ebit

Income Tax Expense

Most indicators from Haemonetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Haemonetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.At present, Haemonetics' Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 25.70, whereas Selling General Administrative is forecasted to decline to about 235.5 M.

	2021	2022	2023	2024 (projected)
Gross Profit	505.5M	615.1M	676.5M	710.4M
Total Revenue	993.2M	1.2B	1.3B	1.4B

Gross Profit Total Revenue

Haemonetics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Short Term Investments
Common Stock Shares Outstanding		-0.68	-0.59	-0.66	0.02	-0.11	0.01	-0.57	-0.19	-0.6	-0.14	-0.68	0.06	-0.15	-0.09	-0.62	-0.63	-0.12	-0.59	-0.62	-0.61	-0.13	0.16	-0.66	-0.02	0.34
Total Assets	-0.68		0.94	0.6	0.5	0.64	0.48	0.87	0.3	0.91	0.58	0.99	0.08	0.59	0.6	0.92	0.93	0.56	0.89	0.96	0.81	0.74	0.04	0.95	0.59	-0.57
Short Long Term Debt Total	-0.59	0.94		0.39	0.47	0.44	0.35	0.97	0.07	0.79	0.46	0.95	-0.02	0.46	0.45	0.97	0.91	0.44	0.8	0.99	0.83	0.66	0.05	0.92	0.59	-0.33
Other Current Liab	-0.66	0.6	0.39		0.16	0.37	0.27	0.36	0.28	0.73	0.2	0.58	-0.04	0.21	0.44	0.46	0.57	0.27	0.63	0.49	0.52	0.32	-0.19	0.51	0.15	-0.43
Total Current Liabilities	0.02	0.5	0.47	0.16		0.54	0.57	0.38	-0.07	0.56	0.59	0.45	-0.21	0.59	0.59	0.3	0.54	0.19	0.65	0.5	0.44	0.7	0.8	0.36	0.65	-0.49
Total Stockholder Equity	-0.11	0.64	0.44	0.37	0.54		0.79	0.3	0.67	0.61	0.75	0.58	0.35	0.74	0.87	0.41	0.49	0.75	0.59	0.46	0.34	0.87	0.12	0.54	0.63	-0.85
Property Plant And Equipment Net	0.01	0.48	0.35	0.27	0.57	0.79		0.29	0.36	0.58	0.41	0.46	0.04	0.41	0.86	0.27	0.38	0.33	0.59	0.35	0.31	0.65	0.23	0.31	0.85	-0.71
Net Debt	-0.57	0.87	0.97	0.36	0.38	0.3	0.29		-0.02	0.71	0.25	0.91	-0.06	0.25	0.34	0.96	0.87	0.35	0.73	0.95	0.78	0.51	0.0	0.89	0.6	-0.18
Retained Earnings	-0.19	0.3	0.07	0.28	-0.07	0.67	0.36	-0.02		0.23	0.36	0.29	0.7	0.36	0.41	0.1	0.01	0.71	0.03	0.06	0.09	0.3	-0.18	0.34	0.11	-0.54
Accounts Payable	-0.6	0.91	0.79	0.73	0.56	0.61	0.58	0.71	0.23		0.57	0.87	0.01	0.57	0.71	0.76	0.82	0.43	0.9	0.84	0.78	0.7	0.11	0.76	0.6	-0.6
Cash	-0.14	0.58	0.46	0.2	0.59	0.75	0.41	0.25	0.36	0.57		0.48	0.18	1.0	0.65	0.41	0.48	0.55	0.56	0.49	0.46	0.86	0.25	0.43	0.28	-0.67
Non Current Assets Total	-0.68	0.99	0.95	0.58	0.45	0.58	0.46	0.91	0.29	0.87	0.48		0.06	0.49	0.54	0.94	0.91	0.53	0.85	0.96	0.82	0.67	0.01	0.97	0.6	-0.49
Non Currrent Assets Other	0.06	0.08	-0.02	-0.04	-0.21	0.35	0.04	-0.06	0.7	0.01	0.18	0.06		0.18	0.15	0.03	-0.08	0.69	-0.24	-0.04	-0.21	0.16	-0.24	0.17	0.05	-0.23
Cash And Short Term Investments	-0.15	0.59	0.46	0.21	0.59	0.74	0.41	0.25	0.36	0.57	1.0	0.49	0.18		0.65	0.41	0.48	0.55	0.56	0.49	0.46	0.86	0.25	0.44	0.28	-0.67
Net Receivables	-0.09	0.6	0.45	0.44	0.59	0.87	0.86	0.34	0.41	0.71	0.65	0.54	0.15	0.65		0.41	0.52	0.55	0.66	0.48	0.42	0.85	0.14	0.42	0.71	-0.78
Non Current Liabilities Total	-0.62	0.92	0.97	0.46	0.3	0.41	0.27	0.96	0.1	0.76	0.41	0.94	0.03	0.41	0.41		0.9	0.48	0.76	0.97	0.79	0.61	-0.17	0.92	0.5	-0.28
Inventory	-0.63	0.93	0.91	0.57	0.54	0.49	0.38	0.87	0.01	0.82	0.48	0.91	-0.08	0.48	0.52	0.9		0.41	0.92	0.95	0.71	0.72	0.08	0.87	0.59	-0.49
Other Current Assets	-0.12	0.56	0.44	0.27	0.19	0.75	0.33	0.35	0.71	0.43	0.55	0.53	0.69	0.55	0.55	0.48	0.41		0.28	0.44	0.23	0.66	-0.17	0.63	0.37	-0.48
Other Stockholder Equity	-0.59	0.89	0.8	0.63	0.65	0.59	0.59	0.73	0.03	0.9	0.56	0.85	-0.24	0.56	0.66	0.76	0.92	0.28		0.85	0.71	0.74	0.2	0.73	0.65	-0.65
Total Liab	-0.62	0.96	0.99	0.49	0.5	0.46	0.35	0.95	0.06	0.84	0.49	0.96	-0.04	0.49	0.48	0.97	0.95	0.44	0.85		0.83	0.68	0.05	0.93	0.58	-0.37
Property Plant And Equipment Gross	-0.61	0.81	0.83	0.52	0.44	0.34	0.31	0.78	0.09	0.78	0.46	0.82	-0.21	0.46	0.42	0.79	0.71	0.23	0.71	0.83		0.5	0.12	0.71	0.36	-0.22
Total Current Assets	-0.13	0.74	0.66	0.32	0.7	0.87	0.65	0.51	0.3	0.7	0.86	0.67	0.16	0.86	0.85	0.61	0.72	0.66	0.74	0.68	0.5		0.2	0.61	0.65	-0.72
Short Term Debt	0.16	0.04	0.05	-0.19	0.8	0.12	0.23	0.0	-0.18	0.11	0.25	0.01	-0.24	0.25	0.14	-0.17	0.08	-0.17	0.2	0.05	0.12	0.2		-0.05	0.31	-0.2
Intangible Assets	-0.66	0.95	0.92	0.51	0.36	0.54	0.31	0.89	0.34	0.76	0.43	0.97	0.17	0.44	0.42	0.92	0.87	0.63	0.73	0.93	0.71	0.61	-0.05		0.51	-0.42
Common Stock Total Equity	-0.02	0.59	0.59	0.15	0.65	0.63	0.85	0.6	0.11	0.6	0.28	0.6	0.05	0.28	0.71	0.5	0.59	0.37	0.65	0.58	0.36	0.65	0.31	0.51		-0.51
Short Term Investments	0.34	-0.57	-0.33	-0.43	-0.49	-0.85	-0.71	-0.18	-0.54	-0.6	-0.67	-0.49	-0.23	-0.67	-0.78	-0.28	-0.49	-0.48	-0.65	-0.37	-0.22	-0.72	-0.2	-0.42	-0.51

Click cells to compare fundamentals

Haemonetics Account Relationship Matchups

Haemonetics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	51.8M	51.3M	51.4M	51.4M	51.4M	42.5M
Total Assets	1.3B	1.8B	1.9B	1.9B	2.2B	2.3B
Short Long Term Debt Total	382.5M	707.6M	773.6M	765.9M	807.8M	848.2M
Other Current Liab	127.7M	86.0M	65.6M	82.0M	185.6M	194.8M
Total Current Liabilities	284.3M	253.5M	442.3M	251.8M	300.4M	161.5M
Total Stockholder Equity	587.1M	731.7M	749.4M	818.0M	960.0M	535.9M
Property Plant And Equipment Net	253.4M	217.6M	258.5M	310.9M	366.6M	185.9M
Net Debt	245.2M	515.3M	514.1M	481.4M	629.0M	660.4M
Retained Earnings	78.5M	158.0M	202.4M	253.2M	360.5M	281.9M
Accounts Payable	50.7M	50.3M	58.4M	63.9M	73.4M	77.0M
Cash	137.3M	192.3M	259.5M	284.5M	178.8M	138.4M
Non Current Assets Total	663.5M	1.1B	1.1B	1.2B	1.4B	1.5B
Non Currrent Assets Other	66.3M	76.9M	63.2M	107.0M	90.5M	99.5M
Cash And Short Term Investments	137.3M	192.3M	259.5M	284.5M	178.8M	140.6M
Net Receivables	165.2M	127.6M	159.4M	179.1M	206.6M	120.7M
Liabilities And Stockholders Equity	1.3B	1.8B	1.9B	1.9B	2.2B	2.3B
Non Current Liabilities Total	395.7M	834.8M	668.0M	865.0M	935.2M	982.0M
Inventory	270.3M	322.6M	293.0M	259.4M	317.2M	333.1M
Other Current Assets	30.8M	51.1M	44.1M	46.7M	66.3M	36.9M
Other Stockholder Equity	553.2M	602.7M	572.5M	594.7M	634.6M	666.4M
Total Liab	680.0M	1.1B	1.1B	1.1B	1.2B	1.3B
Property Plant And Equipment Gross	305.6M	217.6M	869.1M	944.2M	959.2M	1.0B
Total Current Assets	603.6M	693.5M	756.0M	769.7M	768.9M	437.2M
Accumulated Other Comprehensive Income	(45.1M)	(29.5M)	(26.0M)	(30.4M)	(35.6M)	(37.4M)
Short Term Debt	77.0M	17.0M	214.1M	11.8M	10.2M	9.7M
Intangible Assets	133.1M	365.5M	310.3M	275.8M	406.1M	426.4M
Other Liab	48.7M	38.2M	76.9M	108.6M	124.9M	131.1M
Other Assets	14.1M	17.0M	67.7M	58.8M	1.0	0.95
Long Term Debt	305.5M	690.6M	559.4M	754.1M	797.6M	837.4M
Good Will	210.7M	466.4M	467.3M	466.2M	565.1M	593.3M
Property Plant Equipment	253.4M	277.4M	258.5M	310.9M	357.5M	213.6M
Current Deferred Revenue	28.8M	26.3M	31.8M	30.2M	31.2M	22.5M
Net Tangible Assets	243.4M	(100.3M)	(28.1M)	76.0M	68.4M	65.0M
Retained Earnings Total Equity	78.5M	158.0M	202.4M	253.2M	227.9M	230.9M
Long Term Debt Total	305.5M	690.6M	559.4M	754.1M	867.2M	910.6M
Capital Surpluse	553.2M	602.7M	572.5M	594.7M	683.9M	516.6M
Deferred Long Term Liab	10.6M	43.8M	28.7M	36.2M	41.6M	26.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
MSFT	Microsoft

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.375

Earnings Share

2.39

Revenue Per Share

26.77

Quarterly Revenue Growth

0.086

Return On Assets

0.0588

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Haemonetics Ebit vs Income Tax Expense Analysis

Ebit vs Income Tax Expense

Ebit vs Income Tax Expense Correlation Analysis

Correlation Coefficient

Ebit

Income Tax Expense

Haemonetics fundamental ratios Correlations

Haemonetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Haemonetics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Short Long Term Debt Total
Net Debt	+ 0.97	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.97	Short Long Term Debt Total
Intangible Assets	+ 0.97	Non Current Assets Total

Short Term Investments	- 0.85	Total Stockholder Equity
Short Term Investments	- 0.78	Net Receivables
Short Term Investments	- 0.72	Total Current Assets
Short Term Investments	- 0.71	Property Plant And Equipment Net
Non Current Assets Total	- 0.68	Common Stock Shares Outstanding
Total Assets	- 0.68	Common Stock Shares Outstanding